Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719811 | 0.92 | MTNR1A (0.51) | PARP1MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL5768646 | 0.91 | MTNR1A (0.47) | PARP1MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL13056761 | 0.85 | PARP1 (0.41) | PARP1MTNR1AMTNR1BKDM4EALDH1A1 | |
| SCHEMBL5768428 | 0.84 | BACE1 (0.40) | ALDH1A1 | |
| SCHEMBL27989542 | 0.83 | MTNR1A (0.40) | PARP1MTNR1AMTNR1BRAB9ANPC1 | |
| SCHEMBL6326149 | 0.81 | PARP1 (0.39) | PARP1MTNR1AMTNR1BHTR2C | |
| SCHEMBL6328642 | 0.81 | PARP1 (0.37) | PARP1MTNR1AMTNR1BRAB9AALDH1A1 | |
| SCHEMBL6334232 | 0.80 | KDM4E (0.44) | PARP1MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL6325233 | 0.80 | PARP1 (0.37) | PARP1MTNR1AMTNR1B | |
| SCHEMBL6325566 | 0.78 | MCL1 (0.43) | PARP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2392574-B1 | Indolyl pyrrolidines for the treatment of cancer | ARQULE INC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2392574-A1 | Indolyl pyrrolidines for the treatment of cancer | ArQule, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392574-A1 | Indolyl pyrrolidines for the treatment of cancer | ArQule, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2173748-B1 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE INC (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2173748-B1 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE INC (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| EP-2173748-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ArQule, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009002807-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002807-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-6743785-B2 | KINASE INHIBITORS; ANNULATED PYRROLE AND INDOLE RINGS; PYRROLO (3,2,1-HI)INDOLES; 3-(5,5-DIMETHYL-5,6-DIHYDRO-4H-PYRROLO (3,2,1-IJ)QUINOLIN-1-YL)-4-(1,2,3,4-TETRAHYDRO-(1,4) DIAZEPINO(6,7,1-HI)INDOL-7-YL)-PYRROLE-2,5-DIONE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1250334-B1 | Medicaments useful for the treatment of proliferative diseases | LILLY CO ELI (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
| EP-1242420-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044247-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | MKI67, CDKN1A, CDK4 | PARP1 579/4885MTNR1A 1002/4885MTNR1B 1120/4885 |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | MKI67, POLI, DHPS | PARP1 157/4885MTNR1A 2155/4885MTNR1B 1216/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | PARP1 516/4885MTNR1A 904/4885MTNR1B 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.